Naslov
Dopaminergic agonist, pramipexole and cognitive functions in Parkinson’ s disease

Autori
Relja, Maja ; Klepac, Nataša

Izvornik
Movement Disorders (0885-3185) 21 (2006);

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kongresno priopcenje, znanstveni

Ključne riječi
Parkinson's disease; cognition; pramipexole

Sažetak
Objective To evaluate the influence of the dopamine agonist pramipexole on cognitive functions in PD as an add-on therapy to levodopa Background PD has long been conceived to be mainly a motor disorder. In the last few decades it has been increasingly more recognized that many patients with PD will experience cognitive decline in the course of their illness. Dopamine agonists have shown beneficial therapeutic effects on motor symptoms in PD, but their influence on cognitive functions is still controversial. the effects of levodopa and dopamine agonist on cognitive functions have been reported as beneficial as well as deleterious Patients and Methods Fifty-five non-demented idiopathic PD patients were included in the study. All patients were treated with levodopa. Patients were randomly divided in two groups ; first group of 25 patients and second of 30 patients. After first neuropsychological assessment second group have been additionally treated with the dopamine agonist pramipexole. Twenty-five healthy volunteers, matched for age and educational level, with no history of central nervous system disorders, were examined. Controls were also given the MMSE with the same inclusion threshold as the patients (>25). Results Compared to controls PD patients showed inferior performance on Stroop Interference test, Trail Making test, letter fluency and Hooper Visual Organization test. No statistically significant differences (p>0.05)between two groups and first and second neuropsychological assessment was found. Conclusion Compared to controls PD patients showed inferior performance on Stroop Interference test, Trail Making test, letter fluency and Hooper Visual Organization test. No statistically significant differences between two groups and first and second neuropsychological assessment was found. Present findings indicate that pramipexole as add-on therapy to levodopa is safe in non-demented PD patients in terms of the effect on cognitive performance.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA